Advertisement

Drugs & Therapy Perspectives

, Volume 5, Issue 12, pp 1–4 | Cite as

Venlafaxine: another option in major depression

New Drugs and Therapeutics

Keywords

Fluoxetine Imipramine Venlafaxine Clomipramine Oxybutynin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995 Feb; 49(2): 280–94PubMedCrossRefGoogle Scholar
  2. 2.
    1995 Physicians GenRx. St. Louis, Missouri: Mosby-Year Book, Inc. 1995; 1959–62Google Scholar
  3. 3.
    British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 164–73Google Scholar
  4. 4.
    Reversible MAO-A inhibitors offer better tolerability than older antidepressants. Drug Ther Perspect 1994 Sep 19; 4(6): 12–14Google Scholar
  5. 5.
    American Hospital Formulary Service Drug Information. Bethesda: American Society of Hospital Pharmacists, 1995: 1504Google Scholar
  6. 6.
    Frazer A. Antidepressant drugs. Depression 1994; 2: 1–19CrossRefGoogle Scholar
  7. 7.
    Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023–9PubMedCrossRefGoogle Scholar
  8. 8.
    Sellers EM, Ball SE, Cheung SW, et al. Inhibition by venlafaxine (VF) and other 5HT uptake inhibitors of the polymorphic enzyme CYP2D6 [abstract]. 22nd Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, Dec 13–17, 1993; 163Google Scholar
  9. 9.
    Schweizer E, Weise C, Clary C, et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991; 11: 233–6PubMedCrossRefGoogle Scholar
  10. 10.
    Khan A, Fabre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991; 27: 141–4PubMedGoogle Scholar
  11. 11.
    Mendels J, Johnston R, Mattes J, et al. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993; 29: 169–74PubMedGoogle Scholar
  12. 12.
    Clerc GE, Ruimy P, Verdeau-Paillès J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9: 139–43PubMedCrossRefGoogle Scholar
  13. 13.
    Shrivastava RK, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994; 14: 322–9PubMedCrossRefGoogle Scholar
  14. 14.
    Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. In pressGoogle Scholar
  15. 15.
    Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995 Mar; 10 Suppl. 2: 15–20PubMedCrossRefGoogle Scholar
  16. 16.
    Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994 Dec 15; 51: 3033–46PubMedGoogle Scholar
  17. 17.
    Effexor. Hosp Formul 1995 Mar; 30: 128Google Scholar
  18. 18.
    Tips for increasing antidepressant prescribing precision. Drug Ther Perspect 1995 Mar 6; 5(4): 10–12Google Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations